Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Soumerai, J. D.
366  Ergebnisse:
Personensuche X
?
1

LONG‐TERM FOLLOW‐UP OF MULTICENTER PHASE II TRIAL OF ZANUBR..:

Soumerai, J. D. ; Dogan, A. ; Seshan, V....
Hematological Oncology.  41 (2023)  S2 - p. 233-235 , 2023
Link: https://doi.org/10.1002/..
 
?
2

PATTERNS OF IMMUNOGLOBULIN G TESTING AND INFECTION OUTCOMES..:

Soumerai, J. D. ; Yousif, Z. ; Gift, T....
Hematological Oncology.  41 (2023)  S2 - p. 744-745 , 2023
Link: https://doi.org/10.1002/..
 
?
3

REAL‐WORLD OUTCOMES OF PATIENTS (PT) WITH RELAPSED OR REFRA..:

Soumerai, J. ; Wang, L. ; Gu, F...
Hematological Oncology.  41 (2023)  S2 - p. 733-734 , 2023
Link: https://doi.org/10.1002/..
 
?
4

P06.11.B NEUROTOXICITY AND MANAGEMENT OF PRIMARY AND SECOND..:

Karschnia, P ; Arrillaga-Romany, I C ; Eichler, A...
Neuro-Oncology.  25 (2023)  Supplement_2 - p. ii47-ii48 , 2023
Link: https://doi.org/10.1093/..
 
?
5

LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN R/R CHRONIC LYMPHOCY..:

Siddiqi, T. ; Maloney, D. G. ; Kenderian, S. S....
Hematological Oncology.  41 (2023)  S2 - p. 60-62 , 2023
Link: https://doi.org/10.1002/..
 
?
6

P1114: ZANDELISIB ON INTERMITTENT DOSING AS A SINGLE AGENT ..:

Soumerai, J. D. ; Jagadeesh, D. ; Salman, H....
HemaSphere.  6 (2022)  - p. 1004-1005 , 2022
Link: https://doi.org/10.1097/..
 
?
7

P687: A PHASE 1 STUDY WITH THE NOVEL B-CELL LYMPHOMA 2 (BCL..:

Opat, S. ; Cheah, C. Y. ; Lasica, M....
HemaSphere.  6 (2022)  - p. 583-584 , 2022
Link: https://doi.org/10.1097/..
 
?
8

ZANDELISIB, A PI3Kδ INHIBITOR ON INTERMITTENT SCHEDULE (IS)..:

Pagel, J. ; Reddy, N. ; Jagadeesh, D....
Hematological Oncology.  39 (2021)  S2 - p. , 2021
Link: https://doi.org/10.1002/..
 
?
9

TRANSCEND CLL 004: MINIMAL RESIDUAL DISEASE AFTER LISOCABTA..:

Siddiqi, T. ; Dorritie, K.A. ; Soumerai, J.D....
Hematological Oncology.  37 (2019)  S2 - p. 109-110 , 2019
Link: https://doi.org/10.1002/..
 
?
10

THE PI3Kδ INHIBITOR ME‐401 ± RITUXIMAB IN RELAPSED/REFRACTO..:

Zelenetz, A.D. ; Jagadeesh, D. ; Kenkre, V.P....
Hematological Oncology.  37 (2019)  S2 - p. 176-177 , 2019
Link: https://doi.org/10.1002/..
 
?
11

DEFINING PROGRESSION FREE SURVIVAL AFTER MULTIPLE LINES OF ..:

Batlevi, C. ; Alperovich, A. ; Ni, A....
Hematological Oncology.  35 (2017)  S2 - p. 229-230 , 2017
Link: https://doi.org/10.1002/..
 
?
12

TIME FROM DIAGNOSIS TO 2ND TREATMENT IS A PROMISING SURROGA..:

Soumerai, J.D. ; Ni, A. ; Batlevi, C....
Hematological Oncology.  35 (2017)  S2 - p. 230-230 , 2017
Link: https://doi.org/10.1002/..
 
?
13

ME‐401, A NOVEL, ORAL, POTENT AND SELECTIVE INHIBITOR OF PH..:

Ghalie, R.G. ; Pagel, J.M. ; Soumerai, J....
Hematological Oncology.  35 (2017)  S2 - p. 407-407 , 2017
Link: https://doi.org/10.1002/..
 
?
14

A535 Phase II Trial of Bortezomib and Rituximab in Relapsed..:

Ghobrial, IM ; Roccaro, AM ; Matous, J...
Clinical Lymphoma and Myeloma.  9 (2009)  - p. S83-S84 , 2009
Link: https://doi.org/10.1016/..
 
?
15

A533 RAD001: Phase II Trial in Relapsed/Refractory Waldenst..:

Ghobrial, IM ; Roccaro, AM ; Chuma, S...
Clinical Lymphoma and Myeloma.  9 (2009)  - p. S82-S83 , 2009
Link: https://doi.org/10.1016/..
 
1-15